Bolder BioTechnology, uses advanced protein engineering technologies to create proprietary, long-acting human protein pharmaceuticals for the treatment of hematopoietic and endocrine disorders, cancer and infectious diseases. Now talk about achieving milestones…Bolder BioTechnology has been on a roll! Most recently BB was awarded a $685,984 Phase II SBIR grant from the National Institute of Arthritis and [...]

• 230http://clsdf.com/2007/10/bolder-biotechnology-on-a-roll/Bolder+BioTechnology+on+a+Roll2007-10-08+15%3A36%3A00admin

A must-attend CBSA BioBreakfast coming up on 24 October 7:30am to be held at the Denver Museum of Nature & Science. The distinguished panel of Dan Mitchell of Sequel Ventures, Karen Cassidy of Partisan Management Group and Andrew Schwab of 5AM Ventures will be reflecting back upon investment trends of 2007 and will provide insight [...]

• 229http://clsdf.com/2007/10/cbsa-biobreakfast-trends-in-vc-investing/CBSA+BioBreakfast%3A+Trends+in+VC+Investing2007-10-08+14%3A42%3A00admin